EP2119450A3 - Induction de tolérance antigénique mucosale - Google Patents

Induction de tolérance antigénique mucosale Download PDF

Info

Publication number
EP2119450A3
EP2119450A3 EP09169276A EP09169276A EP2119450A3 EP 2119450 A3 EP2119450 A3 EP 2119450A3 EP 09169276 A EP09169276 A EP 09169276A EP 09169276 A EP09169276 A EP 09169276A EP 2119450 A3 EP2119450 A3 EP 2119450A3
Authority
EP
European Patent Office
Prior art keywords
induction
antigens
antigen
organism
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP09169276A
Other languages
German (de)
English (en)
Other versions
EP2119450A2 (fr
EP2119450B1 (fr
Inventor
Pieter Rottiers
Veerle Snoeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intrexon Actobiotics NV
Original Assignee
Actogenix NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actogenix NV filed Critical Actogenix NV
Priority to EP09169276A priority Critical patent/EP2119450B1/fr
Publication of EP2119450A2 publication Critical patent/EP2119450A2/fr
Publication of EP2119450A3 publication Critical patent/EP2119450A3/fr
Application granted granted Critical
Publication of EP2119450B1 publication Critical patent/EP2119450B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/50—Feeding-stuffs specially adapted for particular animals for rodents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Animal Husbandry (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
EP09169276A 2005-11-29 2006-11-29 Induction de tolérance antigénique mucosale pour des auto-antigènes de cellules d'îlot pancréatiques Not-in-force EP2119450B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09169276A EP2119450B1 (fr) 2005-11-29 2006-11-29 Induction de tolérance antigénique mucosale pour des auto-antigènes de cellules d'îlot pancréatiques

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05111467 2005-11-29
EP06830192.8A EP1957100B1 (fr) 2005-11-29 2006-11-29 Induction de tolerance muqueuse a des antigenes
EP09169276A EP2119450B1 (fr) 2005-11-29 2006-11-29 Induction de tolérance antigénique mucosale pour des auto-antigènes de cellules d'îlot pancréatiques

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
EP06830192.8A Division EP1957100B1 (fr) 2005-11-29 2006-11-29 Induction de tolerance muqueuse a des antigenes
EP06830192.8A Division-Into EP1957100B1 (fr) 2005-11-29 2006-11-29 Induction de tolerance muqueuse a des antigenes
EP06830192.8 Division 2006-11-29

Publications (3)

Publication Number Publication Date
EP2119450A2 EP2119450A2 (fr) 2009-11-18
EP2119450A3 true EP2119450A3 (fr) 2010-06-30
EP2119450B1 EP2119450B1 (fr) 2013-02-13

Family

ID=37889980

Family Applications (3)

Application Number Title Priority Date Filing Date
EP16178877.3A Active EP3097924B1 (fr) 2005-11-29 2006-11-29 Induction de tolerance muqueuse au gladine
EP06830192.8A Not-in-force EP1957100B1 (fr) 2005-11-29 2006-11-29 Induction de tolerance muqueuse a des antigenes
EP09169276A Not-in-force EP2119450B1 (fr) 2005-11-29 2006-11-29 Induction de tolérance antigénique mucosale pour des auto-antigènes de cellules d'îlot pancréatiques

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP16178877.3A Active EP3097924B1 (fr) 2005-11-29 2006-11-29 Induction de tolerance muqueuse au gladine
EP06830192.8A Not-in-force EP1957100B1 (fr) 2005-11-29 2006-11-29 Induction de tolerance muqueuse a des antigenes

Country Status (13)

Country Link
US (5) US8748126B2 (fr)
EP (3) EP3097924B1 (fr)
JP (2) JP5410759B2 (fr)
CN (1) CN101316611B (fr)
AU (1) AU2006319216B2 (fr)
BR (1) BRPI0619206A2 (fr)
CA (1) CA2631598C (fr)
DK (1) DK2119450T3 (fr)
ES (2) ES2596855T3 (fr)
HK (1) HK1231371A1 (fr)
PT (1) PT2119450E (fr)
RU (1) RU2420569C2 (fr)
WO (1) WO2007063075A1 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
RU2420569C2 (ru) 2005-11-29 2011-06-10 Актогеникс Нв Индукция толерантности к антигенам через слизистую
PL2347775T3 (pl) 2005-12-13 2020-11-16 President And Fellows Of Harvard College Rusztowania do przeszczepiania komórek
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
CA2672229A1 (fr) * 2006-12-14 2008-06-19 Actogenix N.V. Delivrance de molecules de liaison pour induire une immunomodulation
EP2774621B1 (fr) 2007-01-25 2018-01-24 Intrexon Actobiotics NV Traitement d'une maladie immunitaire par l'administration mucosale d'antigènes
WO2009002401A2 (fr) 2007-06-21 2008-12-31 President And Fellows Of Harvard College Échafaudages pour recueil ou élimination de cellules
FI20075539L (fi) * 2007-07-12 2009-01-13 Valio Oy Maitohappobakteerit, joilla on proinflammatorisia ominaisuuksia
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
WO2009102465A2 (fr) 2008-02-13 2009-08-20 President And Fellows Of Harvard College Dispositifs de programmation cellulaire continue
PT2153841E (pt) 2008-08-15 2012-03-21 Circassia Ltd Vacina compreendendo péptidos amb a 1 para utilização no tratamento de alergia a ambrósia
WO2010018384A1 (fr) 2008-08-15 2010-02-18 Circassia Limited Peptide de l’antigène des cellules t d’allergène destiné à stimuler la production d’il-10
WO2010056143A1 (fr) * 2008-11-13 2010-05-20 Instituto De Medicina Molecular Utilisation d'un adjuvant pour faciliter l'induction d'une tolérance immunitaire
US8753644B2 (en) 2009-02-05 2014-06-17 Circassia Limited Grass peptides for vaccine
US10617640B2 (en) 2009-07-07 2020-04-14 The Research Foundation For The State University Of New York Phosphoserine containing compositions for immune tolerance induction
US20120164189A1 (en) * 2009-07-07 2012-06-28 Balu-Iyer Sathy V Lipidic Compositions for Induction of Immune Tolerance
CA2768552A1 (fr) 2009-07-31 2011-02-03 President And Fellows Of Harvard College Programmation de cellules a des fins de therapie tolerogenique
US20110081320A1 (en) * 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
CN102791849B (zh) 2010-03-10 2014-11-12 株式会社钟化 含乳酸菌制剂
WO2011150235A1 (fr) * 2010-05-27 2011-12-01 Allertein Therapeutics, Llc Méthodes et réactifs de traitement de troubles auto-immuns et/ou de rejet de greffe
JP6104806B2 (ja) 2010-10-06 2017-03-29 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 材料に基づく細胞治療のための注射可能孔形成性ハイドロゲル
WO2012149358A1 (fr) 2011-04-28 2012-11-01 President And Fellows Of Harvard College Échafaudages tridimensionnels macroscopiques préformés injectables pour l'administration minimalement invasive
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
JP6062426B2 (ja) 2011-06-03 2017-01-18 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ インサイチュー抗原生成癌ワクチン
DK2758513T3 (en) 2011-09-23 2018-07-23 Intrexon Actobiotics Nv MODIFIED GRAM POSITIVE BACTERIES AND APPLICATIONS THEREOF
ES2676707T3 (es) 2011-09-23 2018-07-24 Intrexon Actobiotics Nv Bacterias gram positivas modificadas y usos de las mismas
EP2726089A2 (fr) * 2012-02-08 2014-05-07 Premune AB Prévention de troubles inflammatoires chez les mammifères domestiques non humains
LT2838515T (lt) 2012-04-16 2020-03-10 President And Fellows Of Harvard College Mezoporinės silico dioksido kompozicijos, skirtos imuninio atsako moduliavimui
IN2014DN10991A (fr) * 2012-05-25 2015-09-25 Cellectis
JP6219728B2 (ja) * 2014-01-15 2017-10-25 キッコーマン株式会社 Ｆｏｘｐ３陽性制御性Ｔ細胞とＩＦＮ−γ産生ＩＬ−１０産生Ｔ細胞誘導を指標とした、経口免疫寛容物質スクリーニング方法及び経口免疫寛容増強組成物
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
WO2015140648A2 (fr) * 2014-02-21 2015-09-24 Ecole Polytecnique Federale De Lausanne (Epfl) Epfl-Tto Agents thérapeutiques de glycociblage
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
EP2989904A1 (fr) * 2014-07-29 2016-03-02 Heinrich-Heine-Universität Induction de tolérance immunologique au moyen de levure
KR101662898B1 (ko) * 2014-09-02 2016-10-06 서울대학교산학협력단 점막점착성 고분자 및 이의 용도
JP6581208B2 (ja) 2014-12-23 2019-09-25 イリヤ ファーマ エービー 創傷治癒の方法
EP3247384B1 (fr) 2015-01-14 2023-10-04 The Regents of the University of Colorado, a body corporate Méthode de diagnostique in vitro du diabète de type 1 avec des mimotopes de l'insuline
US11786457B2 (en) 2015-01-30 2023-10-17 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
EP3280464A4 (fr) 2015-04-10 2018-09-26 President and Fellows of Harvard College Dispositifs de piégeage de cellules immunitaires et leurs procédés de fabrication et d'utilisation
EP3081227A1 (fr) * 2015-04-15 2016-10-19 Institut National De La Recherche Agronomique Lactococcus lactis produisant du tslp ou il-25 et leurs utilisations comme probiotiques et thérapeutiques
US10857190B2 (en) * 2015-10-06 2020-12-08 Albert Einstein College Of Medicine Microbial hyperswarmers and uses thereof
CN109072197A (zh) 2016-02-06 2018-12-21 哈佛学院校长同事会 重塑造血巢以重建免疫
WO2018013797A1 (fr) 2016-07-13 2018-01-18 President And Fellows Of Harvard College Échafaudages mimétiques de cellules présentant l'antigène et procédés pour les préparer et les utiliser
CA3035151A1 (fr) 2016-09-02 2018-03-08 Intrexon Actobiotics N.V. Bacteries genetiquement modifiees exprimant de facon stable il-10 et l'insuline
CN109983028B (zh) 2016-09-13 2023-10-20 英特瑞克斯顿阿克图比奥帝克斯有限公司 黏膜黏附性微生物
CN108114272A (zh) * 2016-11-28 2018-06-05 上海市第五人民医院 一种构建哮喘免疫耐受模型的方法
CA3076014A1 (fr) * 2017-09-29 2019-04-04 Nantcell, Inc. Proteines antigeniques et methodes associees
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
JP2020000033A (ja) * 2018-06-26 2020-01-09 国立大学法人広島大学 経口免疫寛容誘導剤、これを含有する食品および医薬品、ならびに加工食品の製造方法
US11434291B2 (en) 2019-05-14 2022-09-06 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CN110408579A (zh) * 2019-06-03 2019-11-05 东北农业大学 牛白细胞介素-2重组乳酸菌及其应用
AU2020356592A1 (en) 2019-09-27 2022-04-07 Intrexon Actobiotics Nv D/B/A Precigen Actobio Treatment of celiac disease
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002090551A2 (fr) * 2001-05-03 2002-11-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Souche de lactococcus a auto-confinement
EP1359220A2 (fr) * 2002-05-03 2003-11-05 Her Majesty The Queen in Right of Canada, as represented by The Minister of Agriculture and Agri-Food Canada Plantes transgèniques exprimant une cytokine et un auto-antigene
EP1364586A1 (fr) * 2002-05-24 2003-11-26 Nestec S.A. Produits probiotiques et tolérance orale

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100495A (en) 1975-11-27 1978-07-11 Cselt - Centro Studi E Laboratori Telecomunicazioni Adaptive method of and means for recovering digital signals
US4190495A (en) 1976-09-27 1980-02-26 Research Corporation Modified microorganisms and method of preparing and using same
US4874702A (en) 1980-09-08 1989-10-17 Biogen, Inc. Vectors and methods for making such vectors and for expressive cloned genes
US4888170A (en) 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
US5417986A (en) 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5032510A (en) 1984-09-26 1991-07-16 Eli Lilly And Company Method for expression and secretion in bacillus
EP0176320B1 (fr) 1984-09-26 1990-07-25 Eli Lilly And Company Méthode d'expression et sécrétion en Bacillus
US5591632A (en) 1987-03-02 1997-01-07 Beth Israel Hospital Recombinant BCG
EP0347425B1 (fr) 1987-03-02 1995-12-27 Whitehead Institute For Biomedical Research Vaccin mycobacterien recombinant
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US5330753A (en) 1987-04-29 1994-07-19 President And Fellows Of Harvard College Cholera vaccines
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
US5972685A (en) 1988-07-21 1999-10-26 Iowa State University Research Foundation, Inc. Oral administration of coprostanol producing microorganisms to humans to decrease plasma cholesterol concentration
IE892131A1 (en) 1989-06-30 1991-01-02 Univ Cork Marker genes for genetic manipulation
US5149532A (en) 1989-11-01 1992-09-22 Cedars Sinai Medical Center Method of vaccine or toxoid preparation and immunization by colonization with recombinant microorganisms
DE4006521A1 (de) 1990-03-02 1991-09-05 Bayer Ag Zuckerhaltige polymere zur umhuellung und einbettung von arzneistoffen
GB9006400D0 (en) 1990-03-22 1990-05-23 Ciba Geigy Ag Bacterial vectors
IL99097A0 (en) 1990-09-05 1992-07-15 Akzo Nv Haemophilus paragallinarum vaccine
WO1992015689A1 (fr) 1991-03-05 1992-09-17 The Wellcome Foundation Limited Expression de proteines de recombinaison dans des bacteries attenuees
DE69232561T2 (de) 1991-10-07 2002-11-28 Brigham & Womens Hospital Verfahren zur erhöhung der darmabsorption
IL103530A0 (en) 1991-10-25 1993-03-15 Duphar Int Res Treponema hyodysenteriae vaccine
GB2278358B (en) 1992-02-27 1995-07-26 Lynxvale Ltd Heterologous gene expression in Lactococcus,and the expression products therefrom
US5455034A (en) 1992-06-26 1995-10-03 Kansas State University Research Foundation Fusobacterium necrophorum leukotoxoid vaccine
DE4231764A1 (de) 1992-09-23 1994-03-24 Inst Pflanzengenetik & Kultur Verfahren zur chromosomalen Integration eines Produkt-Gens
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5691185A (en) 1993-10-08 1997-11-25 Chr. Hansen A/S Lactic acid bacterial suppressor mutants and their use as selective markers and as means of containment in lactic acid bacteria
BR9407813A (pt) 1993-10-13 1997-05-06 Gx Biosystems As Nucleases de staphylococcus recombinantes e seu uso na limitação da sobrevivencia de microorganismos elaborados por engenharia genética
IT1270123B (it) 1994-10-05 1997-04-28 Dompe Spa Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
US5733540A (en) 1995-03-08 1998-03-31 Lee; Peter Poon-Hang Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria
WO1996032486A1 (fr) 1995-04-11 1996-10-17 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Procede de construction de vecteurs pour bacteries d'acide lactique comme lactobacillus, qui permet aux bacteries d'exprimer, de secreter et de faire apparaitre des proteines en surface
US5753622A (en) 1995-05-10 1998-05-19 University Technologies International, Inc. Use of epidermal growth factor as a gastrointestinal therapeutic agent
CA2222761A1 (fr) 1995-06-07 1996-12-19 Washington University Systeme bacterien recombine a viabilite limitee par l'environnement
US5824538A (en) 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
GB9518323D0 (en) 1995-09-07 1995-11-08 Steidler Lothar Materials and methods relating to the attachment and display of substances on cell surfaces
GB9521568D0 (en) 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
BR9708387A (pt) 1996-03-28 2000-01-04 Genitrix Llc Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
CA2251780A1 (fr) 1996-04-12 1997-10-23 Peptide Technology Pty. Limited Procedes permettant de traiter des immunopathologies au moyen d'acides gras polyinsatures
CA2252439C (fr) 1996-04-19 2014-09-30 Henry M. Jackson Foundation For The Advancement Of Military Medicine Procede de stimulation d'une reaction immunitaire par administration d'organismes hotes qui expriment l'intimine seule ou sous forme de proteine de fusion associee a un ou plusieurs antigenes
US5972887A (en) 1996-09-19 1999-10-26 The Nemours Foundation Treatment of intestinal epithelial cell malfunctions with Hepatocyte Growth Factor
US5723245A (en) 1996-10-09 1998-03-03 Xerox Corporation Colored toner and developer compositions and process for enlarged color gamut
GB9700939D0 (en) 1997-01-17 1997-03-05 Microbial Technics Limited Therapy
US6685943B1 (en) 1997-01-21 2004-02-03 The Texas A&M University System Fibronectin binding protein compositions and methods of use
ATE346931T1 (de) 1997-06-20 2006-12-15 Intervet Int Bv Clostridium perfringens impfstoff
US6100388A (en) 1998-03-16 2000-08-08 Biogaia Biologies Ab Lactobacilli harboring aggregation gene as a vaccine delivery vehicle
US7183097B1 (en) 1998-05-07 2007-02-27 Universite Libre De Bruxelles Cytotoxin-based biological containment
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
JP5068401B2 (ja) 1998-09-28 2012-11-07 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップ Ｈｐｍｃカプセルを使用する腸及び結腸への送達
WO2000022909A2 (fr) 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systemes d'administration orale
AU770726B2 (en) 1998-10-20 2004-02-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of a cytokine-producing lactococcus strain to treat colitis
EP1194554B1 (fr) 1999-07-05 2006-10-18 Vlaams Interuniversitair Instituut voor Biotechnologie Distribution de peptides en trefle
ES2336647T3 (es) 2000-10-20 2010-04-15 Bioneer A/S Metodo de fermentacion para la produccion de productos genicos heterologos en bacterias de acido lactico.
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
NO318426B1 (no) 2001-10-02 2005-04-18 Neurozym Biotech As Et materiale for a senke konsentrasjonen av patogene tarmpeptider
EP1319410A1 (fr) 2001-12-11 2003-06-18 Société des Produits Nestlé S.A. Utilisation de microorganismes pour l'administration ciblée de substances dans des parties spécifiques de l'intestin
US20040043003A1 (en) 2002-01-31 2004-03-04 Wei Chen Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
DE10208653A1 (de) 2002-02-28 2003-09-18 Medinnova Ges Med Innovationen Mikroorganismus als Träger von Nukleotidsequenzen kodierend für Zellantigene zur Behandlung von Tumoren
US7425449B2 (en) 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same
WO2003096979A2 (fr) 2002-05-14 2003-11-27 The Board Of Trustees Of The Leland Stanford Junior University Pharmacotherapie destinee a une maladie coeliaque
DE60319822T2 (de) 2002-06-19 2009-06-04 Actogenix Nv Verfahren und mittel zur erhöhung der darmabsorption
CA2506031A1 (fr) 2002-11-15 2004-06-03 Vib Vzw Souche de lactobacillus automone comprenant une mutation du gene thya et applications therapeutiques associees
AU2003294473A1 (en) 2002-11-20 2004-06-15 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for celiac sprue
JP4589618B2 (ja) * 2003-11-28 2010-12-01 独立行政法人農業生物資源研究所 免疫調節性機能を誘導する乳酸菌類とその成分
EP1725254A4 (fr) * 2004-02-04 2008-02-13 Univ Columbia Immunotherapie anti-cd3 et specifique d'antigenes pour le traitement de l'auto-immunite
CN1695469A (zh) 2005-05-17 2005-11-16 田星 一种风味益生发酵乳及其制作方法
RU2420569C2 (ru) * 2005-11-29 2011-06-10 Актогеникс Нв Индукция толерантности к антигенам через слизистую
EP2774621B1 (fr) 2007-01-25 2018-01-24 Intrexon Actobiotics NV Traitement d'une maladie immunitaire par l'administration mucosale d'antigènes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002090551A2 (fr) * 2001-05-03 2002-11-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Souche de lactococcus a auto-confinement
EP1359220A2 (fr) * 2002-05-03 2003-11-05 Her Majesty The Queen in Right of Canada, as represented by The Minister of Agriculture and Agri-Food Canada Plantes transgèniques exprimant une cytokine et un auto-antigene
EP1364586A1 (fr) * 2002-05-24 2003-11-26 Nestec S.A. Produits probiotiques et tolérance orale

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BATTAGLIA MANUELA ET AL: "IL-10-producing T regulatory type 1 cells and oral tolerance.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES DEC 2004, vol. 1029, December 2004 (2004-12-01), pages 142 - 153, XP009081544, ISSN: 0077-8923 *
BERMUDEZ-HUMARAN L G ET AL: "Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 71, no. 4, April 2003 (2003-04-01), pages 1887 - 1896, XP002346262, ISSN: 0019-9567 *
BISIKIRSKA B ET AL: "Use ofAnti-CD3 Monoclonal Antibody to Induce Immune Regulation in Type I Diabetes", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES, NEW YORK, NY, US LNKD- DOI:10.1196/ANNALS.1337.001, vol. 1037, 1 January 2004 (2004-01-01), pages 1 - 9, XP003025608, ISSN: 0077-8923, [retrieved on 20060112] *
BRUMEANU T-D ET AL: "T-CELL TOLERANCE AND AUTOIMMUNE DIABETES", INTERNATIONAL REVIEWS OF IMMUNOLOGY, HARWOOD ACADEMIC PUBLISHERS, LONDON, GB, vol. 20, no. 2, 1 January 2001 (2001-01-01), pages 301 - 331, XP009043134, ISSN: 0883-0185 *
MAASSEN C B M ET AL: "Reduced experimental autoimmune encephalomyelitis after intranasal and oral administration of recombinant lactobacilli expressing myelin antigens", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 21, no. 32, 1 December 2003 (2003-12-01), pages 4685 - 4693, XP004469685, ISSN: 0264-410X *
MOWAT A M: "Basic mechanisms and clinical implications of oral tolerance.", CURRENT OPINION IN GASTROENTEROLOGY NOV 1999, vol. 15, no. 6, November 1999 (1999-11-01), pages 546, XP009081553, ISSN: 0267-1379 *
SLAVIN A J ET AL: "Mucosal administration of IL-10 enhances oral tolerance in autoimmune encephalomyelitis and diabetes.", INTERNATIONAL IMMUNOLOGY JUN 2001, vol. 13, no. 6, June 2001 (2001-06-01), pages 825 - 833, XP002427638, ISSN: 0953-8178 *
STEIDLER L ET AL: "Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 66, no. 7, July 1998 (1998-07-01), pages 3183 - 3189, XP002105819, ISSN: 0019-9567 *

Also Published As

Publication number Publication date
US20140322230A1 (en) 2014-10-30
CN101316611B (zh) 2017-05-03
CN101316611A (zh) 2008-12-03
US9526750B2 (en) 2016-12-27
US20100172920A1 (en) 2010-07-08
US20090148389A1 (en) 2009-06-11
RU2420569C2 (ru) 2011-06-10
AU2006319216A1 (en) 2007-06-07
US20170100475A1 (en) 2017-04-13
WO2007063075A1 (fr) 2007-06-07
JP2009521406A (ja) 2009-06-04
EP3097924A1 (fr) 2016-11-30
JP2013189446A (ja) 2013-09-26
ES2405552T3 (es) 2013-05-31
US8748126B2 (en) 2014-06-10
US9539291B2 (en) 2017-01-10
AU2006319216B2 (en) 2012-09-13
US8398995B2 (en) 2013-03-19
ES2596855T3 (es) 2017-01-12
JP5410759B2 (ja) 2014-02-05
PT2119450E (pt) 2013-04-26
EP2119450A2 (fr) 2009-11-18
EP3097924B1 (fr) 2020-01-08
DK2119450T3 (da) 2013-05-06
US10195269B2 (en) 2019-02-05
RU2008126198A (ru) 2010-01-10
EP1957100A1 (fr) 2008-08-20
US20140322266A1 (en) 2014-10-30
HK1231371A1 (zh) 2017-12-22
EP1957100B1 (fr) 2016-07-13
EP2119450B1 (fr) 2013-02-13
CA2631598C (fr) 2017-06-27
CA2631598A1 (fr) 2007-06-07
BRPI0619206A2 (pt) 2011-09-20

Similar Documents

Publication Publication Date Title
EP2119450A3 (fr) Induction de tolérance antigénique mucosale
EP2774621A3 (fr) Traitement d'une maladie immunitaire par l'administration mucosale d'antigènes
WO2006071983A3 (fr) Combinaisons d'antigenes associes a une tumeur dans des compositions pour differents types de cancers
EP3725328A3 (fr) Nouvelles compositions d'adjuvants
WO2007067681A3 (fr) Compositions et méthodes immunostimulatoires
NZ595234A (en) Adjuvanting meningococcal factor h binding protein
EP4269441A3 (fr) Domaine sushi de l'il-15 et de l'il-15ralpha basé sur des modulokines
EP1708749A4 (fr) Adjuvants de vaccins des muqueuses contenant des flagellines bacteriennes comme composante active
WO2008116078A3 (fr) Stimulation d'une réponse immunitaire par des lipides cationiques
WO2005111057A3 (fr) Acides nucleiques immunostimulateurs destines a induire des reactions d'il-10
EP3178490A3 (fr) Compositions à base de protéine f du vrs et procédés de fabrication associés
WO2008021076A3 (fr) Vaccins à base de matrice protéique et procédés de fabrication et d'administration de tels vaccins
EP3263128A3 (fr) Compositions pour l'immunisation contre staphylococcus aureus
WO2004032829A3 (fr) Compositions immunostimulantes et procedes de stimulation d'une reponse immune
EP1800690A3 (fr) Utilisation d'une protéine immunomodulatoire d'origine fongique
WO2008103947A3 (fr) Activation de cellules humaines présentant un antigène par l'intermédiaire de clec-6
WO2009133378A3 (fr) Produits et procédés permettant de stimuler une réponse immunitaire
WO2011070214A8 (fr) Nouveaux conjugués et compositions pour immunothérapie et traitement anti-tumoral
WO2005091856A8 (fr) Proteines derivees de l'immunoglobuline anti-il-13 associees a l'asthme, composition, procedes associes et leur utilisation
WO2008039390A3 (fr) Compositions et procédés pour améliorer la réponse immunitaire à l'aide des chitosanes
WO2006055024A3 (fr) Minicellules employees comme vaccins
EP2572734A3 (fr) Protéines de fusion à base de cytokine pour le traitement des troubles immunitaires
WO2005120564A3 (fr) Compositions vaccinales et methodes correspondantes
WO2006060332A3 (fr) Electroporation of mycobacterium et surexpression d'antigenes dans des mycobacteries
WO2006123230A8 (fr) Compositions pour l'induction specifique d'antigene de la tolerance

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090902

AC Divisional application: reference to earlier application

Ref document number: 1957100

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20110228

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 35/74 20060101ALI20120720BHEP

Ipc: A61K 48/00 20060101ALI20120720BHEP

Ipc: A23K 1/18 20060101ALI20120720BHEP

Ipc: A23L 1/30 20060101ALI20120720BHEP

Ipc: A23K 1/00 20060101ALI20120720BHEP

Ipc: A61K 38/20 20060101ALI20120720BHEP

Ipc: A61K 39/39 20060101ALI20120720BHEP

Ipc: A61K 39/00 20060101AFI20120720BHEP

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AC Divisional application: reference to earlier application

Ref document number: 1957100

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 596113

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006034583

Country of ref document: DE

Effective date: 20130411

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20130418

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20130400562

Country of ref document: GR

Effective date: 20130418

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2405552

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20130531

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130613

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130213

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130513

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130213

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130213

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130213

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130213

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130213

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130213

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130213

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20131114

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006034583

Country of ref document: DE

Effective date: 20131114

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130213

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130213

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130213

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20061129

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131129

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602006034583

Country of ref document: DE

Owner name: INTREXON ACTOBIOTICS NV, BE

Free format text: FORMER OWNER: ACTOGENIX NV, ZWIJNAARDE, BE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: INTREXON ACTOBIOTICS NV, BE

Free format text: FORMER OWNER: ACTOGENIX N.V., BE

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: INTREXON ACTOBIOTICS NV

Effective date: 20161103

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: NL

Ref legal event code: HC

Owner name: INTREXON ACTOBIOTICS N.V.; BE

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME; FORMER OWNER NAME: ACTOGENIX N.V.

Effective date: 20161117

REG Reference to a national code

Ref country code: FR

Ref legal event code: CD

Owner name: INTREXON ACTOBIOTICS NV, BE

Effective date: 20170124

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20191104

Year of fee payment: 14

Ref country code: SE

Payment date: 20191127

Year of fee payment: 14

Ref country code: FI

Payment date: 20191127

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20191125

Year of fee payment: 14

Ref country code: ES

Payment date: 20191202

Year of fee payment: 14

Ref country code: GR

Payment date: 20191127

Year of fee payment: 14

Ref country code: DK

Payment date: 20191127

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20191203

Year of fee payment: 14

Ref country code: AT

Payment date: 20191104

Year of fee payment: 14

REG Reference to a national code

Ref country code: FI

Ref legal event code: MAE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20201130

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 596113

Country of ref document: AT

Kind code of ref document: T

Effective date: 20201129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210608

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201129

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201130

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201130

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201130

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20211126

Year of fee payment: 16

Ref country code: IE

Payment date: 20211129

Year of fee payment: 16

Ref country code: GB

Payment date: 20211129

Year of fee payment: 16

Ref country code: FR

Payment date: 20211124

Year of fee payment: 16

Ref country code: DE

Payment date: 20211126

Year of fee payment: 16

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220203

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20211129

Year of fee payment: 16

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201130

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602006034583

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20221201

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20221129

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20221130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221129

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221129

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221130

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221130